Cover Story
FDA will hold a three-day meeting of the Oncologic Drugs Advisory Committee April 27-29 to consider five indications that received accelerated approvals, but that have not been shown to produce a clinical benefit in confirmatory trials.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Radiation oncologist, global health expert C. Norman Coleman dies of sarcoma at 79
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- FDA’s Harpreet Singh: Overall survival data tells the full story of immune checkpoint inhibitor benefit in NSCLC
Pooled analysis finds correlations between early endpoints and OS in ICI trials - CMS starts paying for patient navigation; ACS offers navigation credentialing program
- Population scientist Monica Baskin is the “Jackie Robinson” of cancer center deputy directors
- Lillian Siu named 2024-2025 president-elect of AACR